Literature DB >> 19826642

A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Nisha Mistry1, Jonathan Shapero, Richard I Crawford.   

Abstract

Drug-induced cutaneous eruptions are named among the most common side effects of many medications. Thus, cutaneous drug eruptions are a common cause of morbidity and mortality, especially in hospital settings. The present article reviews different presentations of drug-induced cutaneous eruptions, with a focus on eruptions reported secondary to the use of interferon and ribavirin. Presentations include injection site reactions, psoriasis, eczematous drug reactions, alopecia, sarcoidosis, lupus, fixed drug eruptions, pigmentary changes and lichenoid eruptions. Also reviewed are findings regarding life-threatening systemic drug reactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826642      PMCID: PMC2776610          DOI: 10.1155/2009/651952

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  99 in total

1.  Oral lichen planus induced by interferon-alpha-N1 in a patient with hepatitis C.

Authors:  P Varela; J Areias; F Mota; A Canelhas; M Sanches
Journal:  Int J Dermatol       Date:  2000-03       Impact factor: 2.736

2.  Grover's disease secondary to ribavirin.

Authors:  I Antunes; F Azevedo; J Mesquita-Guimarães; C Resende; N Fernandes; G MacEdo
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

3.  Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature.

Authors:  S Fukuyama; E Kajiwara; N Suzuki; N Miyazaki; S Sadoshima; K Onoyama
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

4.  Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.

Authors:  A Conde-Taboada; C de la Torre; C Feal; E Mayo; B Gonzalez-Sixto; M J Cruces
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

5.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.

Authors:  C Taylor; D A Burns; M J Wiselka
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

6.  Interferon-induced cutaneous necrosis.

Authors:  D Sasseville; W A Ghamdi; S A Khenaizan
Journal:  J Cutan Med Surg       Date:  1999-10       Impact factor: 2.092

7.  [Skin reactions to interferon alpha in a series of 92 patients with multiple sclerosis].

Authors:  Y Fortuño; J Marcoval; I Gallego; A Moreno; T Arbizu; J Peyrí
Journal:  Med Clin (Barc)       Date:  1999-10-16       Impact factor: 1.725

8.  Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C.

Authors:  Vincent Ho; Anna Mclean; Shaughan Terry
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

9.  Sarcoid-like granulomatous orbital inflammation induced by interferon-alpha treatment.

Authors:  Catherine J Hwang; Roberta E Gausas
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2008 Jul-Aug       Impact factor: 1.746

Review 10.  Dermatomyositis after interferon alpha treatment.

Authors:  L L Dietrich; A J Bridges; M R Albertini
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.738

View more
  17 in total

1.  Arenavirus reverse genetics for vaccine development.

Authors:  Emilio Ortiz-Riaño; Benson Yee Hin Cheng; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Gen Virol       Date:  2013-01-30       Impact factor: 3.891

2.  Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.

Authors:  W W Shanaka I Rodrigo; Emilio Ortiz-Riaño; Christelle Pythoud; Stefan Kunz; Juan C de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.

Authors:  Elżbieta Kłujszo; Piotr Parcheta; Dorota Zarębska-Michaluk; Ewa Ochwanowska; Anna Witkowska; Adriana Rakowska; Lidia Rudnicka; Wiesław Kryczka
Journal:  J Dermatol Case Rep       Date:  2014-12-31

Review 4.  Eczematous Drug Eruptions.

Authors:  Amy E Blum; Susan Burgin
Journal:  Am J Clin Dermatol       Date:  2021-02-15       Impact factor: 7.403

Review 5.  New treatments for chronic hepatitis C: an overview for paediatricians.

Authors:  Daniele Serranti; Giuseppe Indolfi; Massimo Resti
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.

Authors:  Yoko Edahiro; Kohshi Ohishi; Akihiko Gotoh; Katsuto Takenaka; Hirohiko Shibayama; Takayuki Shimizu; Kensuke Usuki; Kazuya Shimoda; Masafumi Ito; Scott A VanWart; Oleh Zagrijtschuk; Albert Qin; Hiroaki Kawase; Narihisa Miyachi; Toshiaki Sato; Norio Komatsu; Keita Kirito
Journal:  Int J Hematol       Date:  2022-04-16       Impact factor: 2.319

Review 7.  Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.

Authors:  Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2012-07-26       Impact factor: 9.079

Review 8.  Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature.

Authors:  Muhammed Sait Dag; Zeynel Abidin Oztürk; Nimet Yılmaz; Hakan Cam; Abdurrahman Kadayıfçı
Journal:  Wien Klin Wochenschr       Date:  2013-08-03       Impact factor: 1.704

9.  Psoriasis and hepatitis C: improvement with interferon.

Authors:  Eyassu Habte-Gabr; Nicolas Lecea
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

10.  Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy.

Authors:  Kamuran Turker; Betul Tas; Murat Ozkaya; Ebru Tas; Aysel Caglar; Umit Seza Tetikkurt
Journal:  Hepat Mon       Date:  2015-03-20       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.